Find your next paid study

M.D. Anderson Cancer CenterNCT07564232

Bladder Squamous Cell CarcinomaLocally Advanced Bladder CarcinomaMalignant Renal Pelvis Neoplasm+8 more

Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of le…

Emory UniversityNCT05756569

Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+5 more

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended …

Inhibrx Biosciences, IncNCT04198766

~$10 – $8,750

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments…

National Cancer Institute (NCI)NCT05665361

~$10 – $5,625

Breath Volatile Organic Compounds (VOC) Analysis Using Proton Transfer Reaction Mass Spectrometry (PTR-MS)

The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve a…

Pancreas CancerHepatocellular CarcinomaLung Cancer+6 more

University of OklahomaNCT07732686

~$10 – $750

Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast Cancer+2 more

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imagi…

Novartis PharmaceuticalsNCT06562192

~$10 – $8,750

Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for …

Differentiated Thyroid Gland CarcinomaThyroid Gland Follicular CarcinomaThyroid Gland Papillary Carcinoma

~$10 – $750

Mayo ClinicNCT05575440

Advanced/Metastatic Solid TumorsColorectal CancerGastric Cancer+5 more

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MC…

~$10 – $7,500

Merus B.V.NCT03526835

Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.

M.D. Anderson Cancer CenterNCT07229417

Pancreatic Ductal Adenocarcinoma (PDAC)

A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) …

The University of Texas Health Science Center, HoustonNCT04990609

Metastatic Renal Cell CarcinomaClear-cell Metastatic Renal Cell CarcinomaNeuroendocrine Tumors+1 more

GU-187: Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC …

Fox Chase Cancer CenterNCT05263050

Phase 4

A Feasibility Clinical Trial of Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization for Patients With Hepatocellular Carcinoma (HCC) for Liver Transplantation

A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevaciz…

Hepatocellular Carcinoma